



Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Paul R Kalra, John G F Cleland, Mark C Petrie, Elizabeth A Thomson, Philip A Kalra, Iain B Squire, Fozia Z Ahmed, Abdallah Al-Mohammad, Peter J Cowburn, Paul W X Foley, Fraser J Graham, Alan G Japp, Rebecca E Lane, Ninian N Lang, Andrew J Ludman, Iain C Macdougall, Pierpaolo Pellicori, Robin Ray, Michele Robertson, Alison Seed, Ian Ford, for the IRONMAN Study Group*



Summary

Background For patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous ferric carboxymaltose administration improves quality of life and exercise capacity in the short-term and reduces hospital admissions for heart failure up to 1 year. We aimed to evaluate the longer-term effects of intravenous ferric derisomaltose on cardiovascular events in patients with heart failure.

Methods IRONMAN was a prospective, randomised, open-label, blinded-endpoint trial done at 70 hospitals in the UK. Patients aged 18 years or older with heart failure (left ventricular ejection fraction $\leq 45\%$) and transferrin saturation less than 20% or serum ferritin less than 100 $\mu\text{g/L}$ were eligible. Participants were randomly assigned (1:1) using a web-based system to intravenous ferric derisomaltose or usual care, stratified by recruitment context and trial site. The trial was open label, with masked adjudication of the outcomes. Intravenous ferric derisomaltose dose was determined by patient bodyweight and haemoglobin concentration. The primary outcome was recurrent hospital admissions for heart failure and cardiovascular death, assessed in all validly randomly assigned patients. Safety was assessed in all patients assigned to ferric derisomaltose who received at least one infusion and all patients assigned to usual care. A COVID-19 sensitivity analysis censoring follow-up on Sept 30, 2020, was prespecified. IRONMAN is registered with ClinicalTrials.gov, NCT02642562.

Findings Between Aug 25, 2016, and Oct 15, 2021, 1869 patients were screened for eligibility, of whom 1137 were randomly assigned to receive intravenous ferric derisomaltose ($n=569$) or usual care ($n=568$). Median follow-up was 2.7 years (IQR 1.8–3.6). 336 primary endpoints (22.4 per 100 patient-years) occurred in the ferric derisomaltose group and 411 (27.5 per 100 patient-years) occurred in the usual care group (rate ratio [RR] 0.82 [95% CI 0.66 to 1.02]; $p=0.070$). In the COVID-19 analysis, 210 primary endpoints (22.3 per 100 patient-years) occurred in the ferric derisomaltose group compared with 280 (29.3 per 100 patient-years) in the usual care group (RR 0.76 [95% CI 0.58 to 1.00]; $p=0.047$). No between-group differences in deaths or hospitalisations due to infections were observed. Fewer patients in the ferric derisomaltose group had cardiac serious adverse events (200 [36%]) than in the usual care group (243 [43%]; difference -7.00% [95% CI -12.69 to -1.32]; $p=0.016$).

Interpretation For a broad range of patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous ferric derisomaltose administration was associated with a lower risk of hospital admissions for heart failure and cardiovascular death, further supporting the benefit of iron repletion in this population.

Funding British Heart Foundation and Pharmacosmos.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Iron deficiency is common in patients with chronic heart failure, irrespective of left ventricular ejection fraction or haemoglobin concentrations, and is independently associated with more severe symptoms, poorer exercise capacity, and an increased risk of hospitalisation and death.^{1–3} Motivated by placebo-controlled trials reporting that intravenous ferric carboxymaltose can improve quality of life and exercise capacity assessed at 24 weeks for ambulatory patients

with heart failure and a reduced ejection fraction,^{4,5} we conducted the Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency (IRONMAN) trial. We aimed to investigate the long-term effects of repeated doses of intravenous ferric derisomaltose on hospital admission due to heart failure and cardiovascular death in a broad range of patients with heart failure and iron deficiency. Given that there are theoretical risks of repeated doses of intravenous iron, including a potential increase in

Lancet 2022; 400: 2199–209

Published Online
November 5, 2022
[https://doi.org/10.1016/S0140-6736\(22\)02083-9](https://doi.org/10.1016/S0140-6736(22)02083-9)

See [Comment](#) page 2158

*Members listed in the appendix (pp 3–7)

Department of Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK (Prof P R Kalra MD); College of Medical, Veterinary and Life Sciences (Prof P R Kalra), School of Cardiovascular and Metabolic Health (Prof J G F Cleland MD, Prof M C Petrie MBChB, N N Lang PhD, P Pellicori MD), and Robertson Centre for Biostatistics (E A Thomson MA, F J Graham MRCP, M Robertson BSc, Prof I Ford PhD) University of Glasgow, Glasgow, UK; Faculty of Science and Health, University of Portsmouth, Portsmouth, UK (Prof P R Kalra); Department of Renal Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK (Prof P A Kalra MD); Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK (Prof P A Kalra); Department of Cardiovascular Sciences, University of Leicester, Leicester, UK (Prof I B Squire MD); Department of Cardiology, Manchester University NHS Foundation Trust, Manchester, UK (F Z Ahmed MD); Department of Cardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK (Prof A Al-Mohammad MD); Department of Infection, Immunity and Cardiovascular Disease, The University of

Sheffield, Sheffield, UK (Prof A Al-Mohammad); Department of Cardiology, University Hospital Southampton NHS Foundation Trust, Southampton, UK (P J Cowburn MD); Wiltshire Cardiac Centre, Great Western Hospitals NHS Foundation Trust, Swindon, UK (P W X Foley MD); Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK (A G Japp MRCP); Department of Cardiology, Royal Brompton and Harefield Hospitals, London, UK (R E Lane FRCP); Department of Cardiology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK (A J Ludman FRCP); Department of Renal Medicine, King's College Hospital, London, UK (Prof I C Macdougall MD); Cardiology Department, St George's University Hospitals NHS Foundation Trust, London, UK (R Ray PhD); Department of Cardiology, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK (A Seed MD)

Correspondence to: Prof Ian Ford, Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ, UK ian.ford@glasgow.ac.uk

See Online for appendix

Research in context

Evidence before this study

A search of PubMed, for the period Jan 1, 2000, to Sept 30, 2022, for publications in English, using the term "heart failure" in combination with a variety of medical terms referring to iron status or its therapeutic use ("iron deficiency", "iron repletion", "intravenous iron", "ferric carboxymaltose", "ferric derisomaltose", "iron isomaltoside 1000", "iron sucrose", "iron supplementation", "iron therapy") identified only two completed randomised trials (CONFIRM-HF and AFFIRM-AHF) that randomly assigned 200 or more patients, followed them up for a minimum of 1 year, and assessed the effects of intravenous iron in patients with heart failure, reduced left ventricular ejection fraction, and iron deficiency. Both trials investigated ferric carboxymaltose. CONFIRM-HF, along with a trial of shorter duration (FAIR-HF) led to guideline recommendations for the use of intravenous ferric carboxymaltose to improve symptoms and quality of life in patients with symptomatic heart failure. However, these trials were not designed to assess the outcome of hospital admission for heart failure or cardiovascular death. AFFIRM-AHF, published in 2020, investigated whether intravenous ferric carboxymaltose reduced the risk of hospital admissions for heart failure or cardiovascular mortality in 1108 patients admitted to hospital with heart failure and iron deficiency over 12 months of follow-up, but narrowly missed its primary efficacy endpoint (rate ratio [RR] 0.79 [95% CI 0.62–1.01]; $p=0.059$).

Added value of this study

To our knowledge, IRONMAN is the first large, randomised trial to investigate safety and the long-term effect on hospital

admissions for heart failure and cardiovascular death of repeated administration of a different iron, intravenous ferric derisomaltose, in patients with heart failure, reduced ejection fraction, and iron deficiency. Ferric derisomaltose can be administered as a high-dose infusion and is already used extensively in other specialties (nephrology, gastroenterology, gynaecology, and pre-operatively). The trial randomly assigned 1137 patients (mostly outpatients without recent hospitalisation for heart failure) with median age 73.4 years (IQR 66.9–79.4) and followed them up for a median of 2.7 years (IQR 1.8–3.6). Compared with usual care, intravenous ferric derisomaltose reduced the numbers of recurrent hospital admissions for heart failure and cardiovascular death (RR 0.82 [95% CI 0.66–1.02]; $p=0.070$). In a prespecified COVID-19 sensitivity analysis, the rate of the primary endpoint was significantly lower in those assigned to intravenous iron than in those assigned to usual care (RR 0.76 [95% CI 0.58–1.00]; $p=0.047$). There were no evident safety issues in terms of infusion reactions or serious adverse events in general, or deaths or hospital admission due to infection in particular, extending the period of safety assessment for treatment with intravenous iron from a maximum of 1 year in previous trials.

Implications of all the available evidence

The consistency of the results from IRONMAN and AFFIRM-AHF suggests that there is a generic benefit accompanying intravenous iron therapy in a broad range of patients with heart failure with iron deficiency, which might be independent of the nature of the iron complex used.

oxidative stress^{6,7} and infection,⁸ IRONMAN prospectively collected safety data to help confirm or refute these concerns.

Methods

Study design

IRONMAN was an investigator-initiated, prospective, randomised, open-label, blinded-endpoint, event-driven trial done at 70 hospital sites in the UK. A Steering Committee, including representatives of the co-sponsors, the University of Glasgow and NHS Greater Glasgow and Clyde Health Board (both Glasgow, UK), oversaw the trial. The trial design has been published previously.⁹ Data were analysed at the Robertson Centre for Biostatistics, University of Glasgow (Glasgow, UK), according to the statistical analysis plan, which is provided in the appendix (pp 283–301) with the protocol. The trial protocol and amendments were approved by a national ethics committee in the UK (Leicester South Research Ethics Committee, trial Integrated Research Application System number 191168), the Medicines and Healthcare products Regulatory Agency, and the Health Research Authority.

Patients

Patients, aged 18 years or older, with new or established symptomatic heart failure, evidence of iron deficiency (serum ferritin <100 µg/L or transferrin saturation <20%), and a left ventricular ejection fraction of 45% or less within the preceding 24 months, were invited to participate. Following written informed consent, patients were screened for additional inclusion and exclusion criteria, with optional consent for record linkage to national databases of hospital admissions and deaths. Patients were required either to have a current or recent (within 6 months) admission to hospital due to heart failure or, for patients not fulfilling either of these criteria, have raised plasma concentrations of natriuretic peptides (NT-proBNP >250 ng/L in sinus rhythm or >1000 ng/L in atrial fibrillation, or BNP >75 ng/L in sinus rhythm or >300 ng/L in atrial fibrillation). Patients were excluded if they had serum ferritin concentrations greater than 400 µg/L or haemoglobin concentration less than 9 g/dL. Iron deficiency is less common in patients with a greater haemoglobin concentration, therefore, to reduce the proportion of patients who did not meet screening criteria, men with a haemoglobin concentration

of more than 14 g/dL and women with a haemoglobin concentration of more than 13 g/dL were excluded. The full list of inclusion and exclusion criteria is in the appendix (pp 120–21) and trial design paper.⁹

Randomisation and masking

Eligible patients were randomly assigned (1:1) to receive ferric derisomaltose or usual care, using a web-based system held by the University of Glasgow, stratified by recruitment context (current or recent hospital admission for heart failure or outpatient with an elevated NT-proBNP or BNP) and trial site. The randomisation list was constructed from randomised, permuted blocks of variable size by a statistician not otherwise involved with the trial at the Robertson Centre for Biostatistics.

Masking patients and staff to intravenous iron infusion (dark brown in colour) is challenging, as every patient visit would need a masked and unmasked research team to be present. This would be particularly difficult in a longer trial. Discussions during the design phase suggested that masking of treatment allocation was not only difficult, but would increase costs and complexity, making it unattractive for patients, funders, and investigators. Because the main trial outcomes, hospital admission for heart failure and cardiovascular death, have a low risk of bias with masked adjudication, intravenous ferric derisomaltose was administered open-label, with masked adjudication of the outcomes.

Procedures

Patients assigned to ferric derisomaltose had their estimated iron deficit determined on the basis of haemoglobin value and bodyweight.⁹ For patients with bodyweight less than 50 kg, the dose of intravenous ferric derisomaltose was 20 mg/kg, irrespective of haemoglobin. If bodyweight was 50 kg to less than 70 kg, the dose of intravenous ferric derisomaltose was 1000 mg if haemoglobin was 10 g/dL or more, or 20 mg/kg if haemoglobin was less than 10 g/dL. Patients with a bodyweight of 70 kg or more received intravenous ferric derisomaltose at 20 mg/kg up to a maximum of 1500 mg if haemoglobin was 10 g/dL or more, or 2000 mg if haemoglobin was less than 10 g/dL.

Patients attended a trial visit 4 weeks after random assignment and every 4 months thereafter until trial completion. In the ferric derisomaltose group, investigators gave intravenous ferric derisomaltose at trial visits if ferritin was less than 100 µg/L or if ferritin was 400 µg/L or less and transferrin saturation was less than 25%. The rationale for using a higher transferrin saturation cutoff for redosing than for inclusion was to try and maintain iron repletion between visits and thereby reduce the risk of patients becoming substantially iron deficient.

Investigators were encouraged to optimise other heart failure therapy in both groups according to contemporary guidelines. Although patients in the usual care group should not have been treated with intravenous iron, they

were permitted to have oral iron at the investigator's discretion, although this was not actively encouraged. Haemoglobin was measured at each trial visit in both groups but, to minimise the use of iron in the usual care group, transferrin saturation and ferritin were measured only in those assigned to receive iron. At 4 months and 20 months, a 6 min walk test was undertaken (where possible) and the Minnesota Living with Heart Failure (MLHFQ) and EQ-5D questionnaires were recorded. We expected that some patients' circumstances would change over the longer duration of follow-up anticipated in IRONMAN, such that they might be unable or reluctant to continue to attend research visits in person. Therefore, the protocol permitted review by telephone or by accessing a patient's health-care records. We anticipated that most patients would consent to record linkage to national databases, ensuring that we could still capture important clinical outcomes.

Outcomes

The primary endpoint consisted of all hospital admissions for heart failure and cardiovascular death analysed using a recurrent events analysis. A clinical event committee (charter available in the appendix pp 302–14) adjudicated all hospital admissions and deaths without access to treatment allocation. Hospital admissions due to heart failure were required to last for more than 24 h to be considered as an endpoint.

Secondary endpoints are shown in the statistical analysis plan (appendix pp 283–301), and included: hospital admissions for heart failure (recurrent events); cardiovascular hospital admission (first event); cardiovascular death or hospital admission for heart failure (first event); overall score of MLHFQ at 4 months; cardiovascular death; EQ-5D visual analogue scale at 4 months; EQ-5D index at 4 months; cardiovascular death or hospital admission for stroke, myocardial infarction or heart failure (first event); all-cause mortality; all-cause hospital admission (first event); all-cause mortality or all-cause unplanned hospital admission (first event); physical domain of MLHFQ at 4 months; physical domain of MLHFQ at 20 months; EQ-5D visual analogue scale at 20 months; EQ-5D index at 20 months; overall score of MLHFQ at 20 months; proportion of days dead or admitted to hospital at 3 years; proportion of quality-adjusted days alive and out of hospital at 1 year; 6-min walk distance at 4 months; and 6-min walk distance at 20 months.

Investigators reported serious adverse events and, even if not serious, blood transfusions and haemorrhages. Serious adverse events were coded using the Medical Dictionary for Regulatory Activities. Deaths and hospital admissions due to infection were safety endpoints. Record linkage to national databases of deaths and hospital discharge summaries (Public Health Scotland and NHS Digital) were used to ensure investigators were aware of all potential events.

For Public Health Scotland see <https://publichealthscotland.scot>

For NHS Digital see <https://digital.nhs.uk>

Statistical analysis

We based power calculations on a time-to-first-event analysis in a Cox proportional hazards model, because of the complexity of power calculations based on recurrent events and uncertainty about whether recurrent event analysis increases statistical power. Because both recruitment and event rates were lower than anticipated, the trial duration had to be extended. These issues were exacerbated by the COVID-19 pandemic. The AFFIRM-AHF trial¹⁰ followed by a meta-analysis of published trials of intravenous iron in patients with heart failure suggested a larger treatment effect than originally anticipated (odds ratio 0.73 [95% CI 0.59–0.90]).¹¹ For these reasons, the power calculations were revised and the assumed hazard ratio changed from 0.80 to 0.75, requiring 379 patients to reach a first primary endpoint in order to provide 80% power at the 5% significance level.

Analyses included treatment group and recruitment context as covariates. All efficacy analyses were done in the validly randomly assigned population. Recurrent events were analysed by the method of Lin and colleagues,¹² with treatment effect estimated in the form of rate ratios and 95% CIs, and mean frequency functions displayed using the method of Ghosh and Lin.¹³ Prespecified subgroup analyses were done for the primary endpoint. An interaction term between randomly assigned treatment group and the subgroup variable was added to the fitted model and tested for significance. Primary and secondary endpoints were analysed hierarchically in the order given in the statistical analysis plan. Each outcome was analysed sequentially with a requirement that a p value would not be interpreted as meaningful unless the analysis of the previous outcome was significant with a p value of less than 0.05. Time-to-first-event outcomes were analysed

using Cox proportional hazards models and displayed graphically using cumulative incidence functions or Kaplan-Meier curves as appropriate. Non-proportionality of hazards was assessed for each clinical outcome by adding an interaction of treatment with the logarithm of time to each model and testing for the significance of these interactions. Quality of life scores and 6 min walk test results were analysed using analysis of covariance with multiple imputation for missing values, except results for the 6 min walk test at 20 months, where the degree of missingness, largely due to the COVID-19 pandemic, was considered too great for valid imputation.

Safety analyses were done for patients assigned to ferric derisomaltose who received at least one infusion and all patients assigned to usual care. Proportions of patients having serious adverse events in each system organ class were compared between treatment groups assuming binomial distributions.

Consistent with regulatory^{14,15} and other¹⁶ guidance to reduce the effect of the COVID-19 pandemic on the trial results, we prespecified a sensitivity analysis including all patients randomly assigned until March 31, 2020, around the start of the first national lockdown in the UK. The censoring date was Sept 30, 2020, based on the assumption that most patients would remain iron replete for at least 6 months from their last dose of ferric derisomaltose or last test showing iron repletion. Very few research patients could be seen in person in and around the time of the COVID-19 lockdown. At the request of a referee we carried out two additional post-hoc sensitivity analyses. In the first, the COVID-19 sensitivity analysis was censored at March 31, 2020, and in the second, censoring was further set at 1 year to permit comparison with results from the AFFIRM-AHF trial.

An Independent data monitoring committee reviewed trial data on a regular basis and conducted preplanned interim analyses of the primary endpoint when approximately 50% and 70% of the target number of first primary endpoints had been reached, requiring a p value of less than 0.001 to recommend early stopping. No p value adjustments were made for these interim analyses.

All analyses used SAS version 9.4 or R version 3.6.1. This trial is registered with ClinicalTrials.gov, NCT02642562.

Role of the funding source

The funders of the study had no role in the trial design, data collection, data analysis, data interpretation, or writing of the report. Pharmacosmos was allowed to review and comment on the manuscript before submission with no obligation to accept their comments.

Results

Between Aug 25, 2016, and Oct 15, 2021, 1869 patients were screened for eligibility, of whom 1137 were validly randomly assigned (one patient on a heart transplant list was randomly assigned in error) to receive intravenous ferric derisomaltose (n=569) or usual care (568; figure 1).




Figure 1: Trial profile

	Ferric derisomaltose group (n=569)	Usual care group (n=568)
Age, years	73.2 (66.7–80.1)	73.5 (67.1–79.1)
Gender		
Female	142 (25%)	158 (28%)
Male	427 (75%)	410 (72%)
BMI, kg/m ²	28.5 (24.7–32.6)	28.3 (24.7–32.5)
Race		
White	519 (91%)	524 (92%)
Black	12 (2%)	7 (1%)
Asian	35 (6%)	31 (5%)
Other	3 (1%)	6 (1%)
Recruitment context		
Admitted to hospital for heart failure and expected to survive to discharge	80 (14%)	84 (15%)
Admitted to hospital for heart failure within past 6 months	106 (19%)	102 (18%)
Outpatient with raised natriuretic peptide concentration	383 (67%)	382 (67%)
New York Heart Association functional classification		
II	328 (58%)	320 (56%)
III	230 (40%)	238 (42%)
IV	11 (2%)	10 (2%)
Heart rate, beats per min	70 (60–80)	69 (40–79)
Systolic blood pressure, mm Hg	119 (106–132)	119 (106–133)
Left ventricular ejection fraction	32% (25–37)	35% (26–38)
Principal cause of heart failure		
Ischaemic	331 (58%)	316 (56%)
Non-ischaemic	177 (31%)	196 (35%)
Unknown	61 (11%)	56 (10%)
Medical history		
Hospital admission for heart failure	337 (59%)	324 (57%)
De novo hospital admission for heart failure	51 (9%)	64 (11%)
Atrial fibrillation	284 (50%)	250 (44%)
Acute coronary syndrome	292 (51%)	285 (50%)
Hypertension	297 (52%)	315 (55%)
Diabetes	252 (44%)	269 (47%)
Device therapy		
Implantable cardioverter-defibrillator	91 (16%)	72 (13%)
Cardiac resynchronisation therapy	125 (22%)	118 (21%)
Haemoglobin, g/dL	12.1 (11.2–12.8)	12.1 (11.2–12.9)
Transferrin saturation	15% (11–20)	15% (10–19)
Ferritin, µg/L	49.0 (30.0–86.0)	50.0 (30.0–85.0)
Estimated glomerular filtration rate calculated by Chronic Kidney Disease Epidemiology Collaboration, mL/min per 1.73 m ²	51.7 (38.1–68.1)	50.1 (37.8–68.6)

(Table 1 continues in next column)

	Ferric derisomaltose group (n=569)	Usual care group (n=568)
(Continued from previous column)		
Heart failure medication		
Loop diuretic	458 (80%)	468 (82%)
Angiotensin-converting enzyme inhibitor	271 (48%)	281 (49%)
Angiotensin receptor blocker	90 (16%)	113 (20%)
Sacubitril-valsartan	130 (23%)	110 (19%)
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or sacubitril-valsartan	486 (85%)	498 (88%)
β blocker	500 (88%)	509 (90%)
Mineralocorticoid receptor antagonist	325 (57%)	307 (54%)
Digoxin	70 (12%)	65 (11%)
Glucose-lowering medication		
Any	223 (39%)	239 (42%)
Insulin	80 (14%)	101 (18%)
Sodium-glucose cotransporter-2 inhibitor	15 (3%)	14 (2%)
Data are median (IQR) or n (%).		
Table 1: Baseline characteristics		

The median duration of follow-up was 2.7 years (IQR 1.8–3.6), with a maximum of 5.4 years. Most patients (1105 [97%]) consented to record linkage. Only 19 (2%) patients withdrew consent for any follow-up; a further 11 (1%) were lost to follow-up (figure 1). As the trial progressed there was a decline in patients attending follow-up visits in person. For example, at 12 months, 306 (71%) of 432 reviews for patients assigned to iron and 274 (66%) of 414 reviews for those assigned to standard care were in person (appendix p 8).

Patient characteristics and cardiovascular treatments were well balanced at baseline (table 1). The median age of patients was 73 years (IQR 63–79); 300 (26%) were women and 837 (74%) were men; 164 (14%) were recruited during a hospital admission for heart failure, 208 (18%) had an admission for heart failure within the previous 6 months, and 765 (67%) were enrolled from outpatient clinics and had raised NT-proBNP or BNP (table 1).

Of the 569 patients assigned to ferric derisomaltose, 559 (98%) received at least one dose, 217 (38%) received only one infusion, 226 (40%) received two infusions, 81 (14%) received three infusions, and 35 (6%) received between four and nine infusions. Due to restrictions on in-person research clinic visits during the COVID-19 pandemic, few patients had repeat dosing with ferric derisomaltose between March, 2020, and the end of the trial. The mean total dose in year 1 was 1978 mg (SD 949), in year 2 was 427 mg (728), and in year 3 was 314 mg (702). In each year, patients not receiving a dose were recorded as having a dose of zero. Of the 568 participants assigned

	Ferric derisomaltose group (n=569)	Usual care group (n=568)	Estimated treatment effect (95% CI)	p value
Primary endpoint				
Cardiovascular death and hospital admission for heart failure, number of events (rate per 100 patient-years)	336 (22.4)	411 (27.5)	0.82 (0.66 to 1.02)*	0.070
Secondary endpoints				
Hospital admissions for heart failure, number of events (rate per 100 patient-years)	250 (16.7)	313 (20.9)	0.80 (0.62 to 1.03)*	0.085
Cardiovascular hospital admission, n (%)	254 (45%)	273 (48%)	0.90 (0.76 to 1.07)†	0.24
Cardiovascular death or hospital admission for heart failure, n (%)	198 (35%)	231 (41%)	0.84 (0.70 to 1.02)†	0.081
Overall score of Minnesota Living with Heart Failure questionnaire at 4 months, least-squares mean (SE)	36.9 (1.2)	40.2 (1.2)	-3.33 (-6.67 to 0.00)‡	0.050
Cardiovascular death, n (%)	119 (21%)	138 (24%)	0.86 (0.67 to 1.10)†	0.23
EQ-5D visual analogue scale at 4 months, least-squares mean (SE)	63.2 (0.9)	63.0 (1.0)	0.20 (-2.47 to 2.87)‡	0.88
EQ-5D index at 4 months, least-squares mean (SE)	0.61 (0.01)	0.60 (0.01)	0.01 (-0.02 to 0.04)‡	0.64
Cardiovascular death or hospital admission for stroke, myocardial infarction, or heart failure, n (%)	209 (37%)	246 (43%)	0.83 (0.69 to 1.00)†	0.045
All-cause mortality, n (%)	184 (32%)	193 (34%)	0.95 (0.78 to 1.17)†	0.64
All-cause hospital admission, n (%)	351 (62%)	370 (65%)	0.91 (0.79 to 1.05)†	0.21
All-cause mortality or all-cause unplanned hospital admission, n (%)	365 (64%)	392 (69%)	0.90 (0.78 to 1.03)†	0.13
Physical domain of Minnesota Living with Heart Failure questionnaire at 4 months, least-squares mean (SE)	18.2 (0.5)	20.2 (0.5)	-1.98 (-3.42 to -0.54)‡	0.0071
Physical domain of Minnesota Living with Heart Failure questionnaire at 20 months, least-squares mean (SE)	19.4 (0.6)	20.6 (0.6)	-1.16 (-2.93 to 0.62)‡	0.20
EQ-5D visual analogue scale at 20 months, least-squares mean (SE)	59.9 (1.3)	59.4 (1.3)	0.54 (-2.86 to 3.94)‡	0.75
EQ-5D index at 20 months, least-squares mean (SE)	0.57 (0.01)	0.55 (0.01)	0.01 (-0.03 to 0.05)‡	0.57
Overall score of Minnesota Living with Heart Failure questionnaire at 20 months, least-squares mean (SD)	40.1 (1.5)	42.7 (1.5)	-2.57 (-6.72 to 1.59)‡	0.23
Proportion of days dead or admitted to hospital at 3 years, mean (SD)	14.9% (26.8)	17.2 (28.7)	-2.28 (-5.49 to 0.93)	0.17
Proportion of quality adjusted days alive and out of hospital at 1 year, mean (SD)	78.4% (16.8)	76.6 (17.7)	1.76 (-0.27 to 3.73)	0.085
6 min walk distance (m) at 4 months, least-squares mean (SE)	286.1 (9.6)	287.7 (9.6)	-1.6 (-28.2 to 24.9)‡§	0.90
6 min walk distance (m) at 20 months, least-squares mean (SE)	252.9 (13.7)	288.8 (13.9)	-35.9 (-74.4 to 2.64)¶	0.068

All comparisons are of the ferric derisomaltose group with the usual care group. *Rate ratio (estimated using the method of Lin and colleagues²³). †Hazard ratio (estimated from Cox proportional hazards models). ‡Estimated mean difference using multiple imputation and Rubin's rules. §Sample sizes after imputation were based on those able and willing to conduct the test at baseline and who could potentially have carried out the test at 4 months; ferric derisomaltose group n=335 and usual care group n=314. ¶Estimated mean difference based on limited data (193 patients [98 in the ferric derisomaltose group and 95 in the usual care group]).

Table 2: Primary and secondary endpoints

to usual care, 95 (17%) received intravenous iron, with 69 (12%) receiving one infusion, 21 (4%) receiving two infusions, and six (1%) receiving between three and five infusions. In year 1, 48 (8%) patients in the usual care group received intravenous iron, in year 2, 35 (6%) patients received intravenous iron, and in year 3, 18 (3%) patients received intravenous iron.

Transferrin saturation and ferritin were recorded after baseline only in those assigned to ferric derisomaltose. Transferrin saturation increased from a mean of 16% (SD 8) at baseline to 30% (SD 10) at 4 weeks, then decreased to a mean of around 26% thereafter (appendix p 9). Ferritin increased from a mean of 70 µg/L (SD 64) at baseline to 514 µg/L (SD 264) at 4 weeks, then stabilised at mean values of about 450 µg/L thereafter (appendix p 10). For patients assigned to usual care, mean haemoglobin values for those who survived and were tested increased gradually over the course of the trial (appendix p 11). For patients assigned to ferric derisomaltose, haemoglobin increased from 12.1 g/dL (SD 1.1) at baseline to 12.8 g/dL (SD 1.4) at 4 months and remained stable thereafter (appendix pp 9, 11).

336 primary endpoints (22.4 per 100 patient-years) occurred in those assigned to ferric derisomaltose and 411 (27.5 per 100 patient-years) in those assigned to usual care (rate ratio [RR] 0.82 [95% CI 0.66–1.02]; p=0.070; table 2, figure 2). No heterogeneity across prespecified subgroups was observed (appendix pp 12–13). Secondary clinical outcomes generally favoured patients assigned to ferric derisomaltose over patients assigned to usual care, although most differences were not statistically significant (table 2). For the expanded outcome of hospitalisation for stroke, myocardial infarction, heart failure, or cardiovascular death, significantly fewer patients assigned to ferric derisomaltose had such an event compared with the usual care group (table 2). There was no evidence of non-proportionality of hazards for the analyses of the primary and secondary clinical endpoints (appendix p 14).

At 4 months, those randomised to ferric derisomaltose had a better overall quality of life score and physical domain score on the MLHFQ compared with those in the usual care group (table 2). There were no differences between the groups in these scores at 20 months, in the EQ-5D scores at 4 or 20 months, or in the 6 min walk test distance at 4 months (table 2).

A similar number of blood transfusions and haemorrhages occurred in each group (appendix p 17). There was no evidence of an increase in serious adverse events with ferric derisomaltose for any system organ class as defined in the Medical Dictionary for Regulatory Activities (table 3). Fewer patients assigned to ferric derisomaltose than usual care had serious adverse cardiac events (table 3). The excess in events for patients in the usual care group appeared to be due to heart failure, acute coronary events, and cardiac arrest (appendix pp 18–19). For infections, there were a similar number of hospital admissions and deaths for those

assigned to ferric derisomaltose and usual care (table 3). One infusion reaction associated with intravenous ferric derisomaltose was reported. The patient had vomiting, back pain, and dizziness soon after commencing infusion, with full recovery after overnight observation.

All COVID-19 sensitivity analyses included 91% of all patients randomly assigned (527 to ferric derisomaltose and 536 to usual care). The prespecified COVID-19 sensitivity analysis, with follow-up censored at Sept 30, 2020, generally suggested a larger benefit from ferric derisomaltose than in the main analysis. For the primary outcome, the RR was nominally statistically significant (table 4). In a post-hoc COVID-19 sensitivity analysis, which censored follow-up at March 31, 2020, results, although associated with slightly enhanced treatment effects, were not substantially different (appendix p 15). In a further post-hoc analysis in which patients were further censored at 1 year of follow-up to enable closer comparison with the results of the AFFIRM-AHF trial, there appeared to be a much greater increase in the magnitude of the treatment effect. For the primary endpoint the RR was 0.66 (95% CI 0.48–0.91; $p=0.011$; appendix p 16).

Discussion

In the IRONMAN trial, the rate per 100 patient-years of the primary outcome of recurrent hospitalisations for heart failure and cardiovascular death was numerically lower for patients randomly assigned to receive ferric derisomaltose than for those assigned to usual care, although the difference was not statistically significant. Other cardiovascular outcome measures generally favoured ferric derisomaltose, including fewer serious adverse cardiovascular events and improvements at 4 months in overall and physical domain scores of MLHFQ. Intravenous ferric derisomaltose also appeared to be safe and well tolerated, with only one probable infusion-related reaction and no increase in infection-related adverse events compared with usual care. However, neither EQ-5D scores nor exercise capacity improved in the ferric derisomaltose group compared with usual care.

During the COVID-19 pandemic in 2020 and 2021, patient recruitment slowed or ceased. Many patients were not permitted or did not want to attend clinics for research purposes. Therefore, blood tests to detect recurrent iron deficiency and redosing with iron were often impossible. Some patients randomly assigned to receive ferric derisomaltose might not have received enough to maintain iron repletion. Many hospitals introduced day-care intravenous diuretic treatment for decompensated heart failure during the pandemic—events not systematically recorded or included as endpoints in IRONMAN. Although the study was well powered to detect the benefit suggested by previous studies, the power calculations could not account for the dilution of the treatment effect caused by the reduction in redosing during the extended period of the pandemic. To try to reduce the effect of COVID-19 on the trial, a prespecified




Figure 2: Estimated mean frequency functions and cumulative incidence curves for key cardiovascular outcomes

(A) Cumulative events for the primary efficacy end point (all hospital admissions for heart failure and cardiovascular death). (B) Cumulative events for all hospital admissions for heart failure. Both A and B show recurrent events plotted in the form of mean frequency functions. (C) Rate of cardiovascular death. (D) Rate of hospital admission for heart failure, stroke or myocardial infarction, or cardiovascular death (first events). Both C and D show cumulative incidence functions, correcting for the competing risk of non-cardiovascular death. The HRs (with 95% CIs) and RRs (with 95% CIs) were adjusted for the baseline stratification variable of recruitment context (in hospital for heart failure, recent hospital admission for heart failure [within 6 months], or with elevated natriuretic peptide level). HR=hazard ratio. RR=rate ratio.

COVID-19 sensitivity analysis was done, including all patients randomly assigned (91% of the total cohort) around the start of the first UK national lockdown and including all events for a further 6-month follow-up. In this analysis, the rate of the primary endpoint was lower in those assigned to intravenous iron and nominally statistically significant. In a post-hoc analysis in which patients were further censored at 1 year of follow-up to enable closer comparison with the AFFIRM-AHF trial, the magnitude of the treatment effect appeared to be further enhanced.

Most trials of intravenous iron in patients with heart failure have investigated ferric carboxymaltose. To our knowledge, IRONMAN is the first large heart failure trial evaluating ferric derisomaltose, which can be given as a rapid, high-dose infusion. Our results are, in many respects, similar to those of the AFFIRM-AHF trial,

	Ferric derisomaltose group (n=559)	Usual care group (n=568)	Difference (95% CI)	p value
Serious adverse events by system organ class, n (%)				
All	410 (73%)	435 (77%)	-3.24 (-8.30 to 1.82)	0.21
Cardiac	200 (36%)	243 (43%)	-7.00 (-12.69 to -1.32)	0.016
Infections and infestations	142 (25%)	162 (29%)	-3.12 (-8.30 to 2.06)	0.24
Surgical and medical	80 (14%)	74 (13%)	1.28 (-2.73 to 5.29)	0.53
Gastrointestinal	56 (10%)	64 (11%)	-1.25 (-4.85 to 2.35)	0.50
Injury, poisoning, and procedural	59 (11%)	63 (11%)	-0.54 (-4.16 to 3.09)	0.77
Respiratory, thoracic, and mediastinal	48 (9%)	67 (12%)	-3.21 (-6.74 to 0.32)	0.074
Renal and urinary	55 (10%)	64 (11%)	-1.43 (-5.01 to 2.16)	0.43
General and administration site	57 (10%)	52 (9%)	1.04 (-2.41 to 4.49)	0.55
Nervous system	54 (10%)	45 (8%)	1.74 (-1.57 to 5.04)	0.30
Metabolism and nutrition	31 (6%)	49 (9%)	-3.08 (-6.07 to -0.09)	0.043
Vascular disorders	34 (6%)	42 (7%)	-1.31 (-4.24 to 1.61)	0.38
Neoplasms benign, malignant, and unspecified	22 (4%)	21 (4%)	0.24 (-2.00 to 2.48)	0.83
Musculoskeletal and connective tissue	19 (3%)	25 (4%)	-1.00 (-3.26 to 1.26)	0.38
Prespecified safety endpoints				
Deaths due to infection, n (%)	34 (6%)	28 (5%)	1.22 (0.74 to 2.02)*	0.43
Hospitalisations due to infection, n (rate per 100 patient-years)	175 (11.7)	213 (14.2)	0.82 (0.62 to 1.08)†	0.16

Values are numbers of patients with at least one event in each category. *Hazard ratio (estimated using a Cox proportional hazards model). †Rate ratio (estimated using a negative binomial regression model).

Table 3: Serious adverse events by Medical Dictionary for Regulatory Activities system organ class and prespecified safety endpoints

	Ferric derisomaltose group (n=527)	Usual care group (n=536)	Estimated treatment effect (95% CI)	p value
Primary endpoint				
Cardiovascular death and hospital admission for heart failure, number of events (rate per 100 patient-years)	210 (22.3)	280 (29.3)	0.76 (0.58-1.00)*	0.047
Secondary endpoints				
Hospital admissions for heart failure, number of events (rate per 100 patient-years)	163 (17.3)	218 (22.8)	0.76 (0.56-1.03)*	0.077
Cardiovascular hospital admission, n (%)	177 (34%)	205 (38%)	0.86 (0.70-1.05)†	0.14
Cardiovascular death or hospital admission for heart failure, n (%)	127 (24%)	160 (30%)	0.80 (0.63-1.01)†	0.055
Cardiovascular death, n (%)	67 (13%)	86 (16%)	0.79 (0.57-1.09)†	0.15
Cardiovascular death or hospital admission for stroke, myocardial infarction, or heart failure, n (%)	137 (26%)	175 (33%)	0.78 (0.62-0.98)†	0.030
All-cause mortality, n (%)	103 (20%)	115 (21%)	0.91 (0.70-1.19)†	0.48
All-cause hospital admission, n (%)	260 (49%)	288 (54%)	0.89 (0.75-1.05)†	0.18
All-cause mortality or all-cause unplanned hospital admission, n (%)	271 (51%)	303 (57%)	0.89 (0.75 to 1.04)†	0.15

All comparisons are of the ferric derisomaltose group with the usual care group. *Rate ratio (estimated using the method of Lin and colleagues²³). †Hazard ratio (estimated from Cox proportional hazards models).

Table 4: Primary and secondary endpoints in the COVID-19 analysis, censoring follow-up on Sept 30, 2020

which included 1108 patients admitted to hospital for heart failure who also had evidence of iron deficiency, and randomly assigned them to intravenous ferric carboxymaltose or placebo.^{10,17} In AFFIRM-AHF, the RR for the primary endpoint of total heart failure hospital admissions and cardiovascular death at 12 months was 0.79 (95% CI 0.62-1.01; p=0.059), but in a COVID-19 sensitivity analysis, was 0.75 (0.59-0.96; p=0.024).¹⁰ The relative benefits of intravenous iron appear remarkably similar between the two trials. Although neither AFFIRM-AHF nor IRONMAN met their primary endpoints, the totality of evidence suggests that intravenous administration of iron does reduce hospital admissions for heart failure, although uncertainty persists about a reduction in cardiovascular mortality.¹¹ The two trials in combination support the use of intravenous iron in patients with heart failure and iron deficiency.

There are some important differences between IRONMAN and AFFIRM-AHF. Whereas AFFIRM-AHF recruited patients during a hospital admission for heart failure, IRONMAN mostly enrolled outpatients who did not have a recent hospital admission for heart failure. Patients in IRONMAN were at a lower risk of events but were also older than in AFFIRM-AHF, extending our current understanding of the benefits of intravenous iron to a much broader range of patients with heart failure. Follow-up was longer in IRONMAN (median follow-up 2.7 years) compared with AFFIRM-AHF, in which intravenous iron was not given after 24 weeks and follow-up stopped at 12 months.¹⁰ Therefore, IRONMAN provides important data on the longer-term safety of intravenous ferric derisomaltose, showing no excess of serious adverse events, including infections. In IRONMAN, no biochemical data regarding phosphate concentrations were collected; it is recognised that dosing with ferric carboxymaltose might be associated with biochemically significant hypophosphataemia, although the long-term clinical relevance remains to be elucidated.¹⁸ No heterogeneity in the effect of treatment on the primary endpoint was observed across prespecified subgroups in IRONMAN. In AFFIRM-AHF, there was a suggestion that patients with ischaemic heart disease obtained greater benefit for the primary endpoint and total hospital admissions for heart failure;¹⁹ similar results were observed in IRONMAN, but the benefit was not statistically significant. Clarification is required from results of further trials and individual-patient meta-analyses. Finally, the COVID-19 pandemic had a more profound effect on the conduct of the IRONMAN trial, restricting intravenous iron dosing after March, 2020, whereas in AFFIRM-AHF dosing was unaffected.

Previous trials have shown that intravenous iron can improve quality of life when assessed to 24 weeks.^{4,5} In IRONMAN, we also found a statistically significant improvement in quality of life at 4 months when assessed by MLHFQ, but this was not apparent at the 20-month visit. This is likely to have been affected by a reduction in

face-to-face attendance as the trial progressed, resulting in patients not being redosed when necessary. This will have been compounded by some patients in the usual care group receiving intravenous iron.

There remains debate as to which clinically available blood tests accurately identify iron deficiency in patients with heart failure.³ For example, hyperferritinaemia is recognised to associate with chronic inflammatory conditions such as heart failure. IRONMAN used a definition based on transferrin saturation, ferritin, or both—similar but not identical to the criteria used in most previous trials of intravenous iron in heart failure^{4,5,10} that have been adopted by guidelines.^{20,21} To keep patients iron replete, redosing of intravenous iron was recommended in IRONMAN if ferritin was less than 100 µg/L or transferrin saturation was less than 25%, provided ferritin was less than or equal to 400 µg/L. Recent data suggest that treating to a higher ferritin target of 600–700 µg/L might improve cardiovascular outcomes, at least in patients receiving haemodialysis.²² These data cannot be extrapolated to patients with heart failure and it remains uncertain as to whether redosing to gain higher ferritin is more efficacious and safe in patients with heart failure.

Trials consistently show that giving intravenous iron to patients with heart failure who are thought to be iron deficient increases mean haemoglobin concentration by about 0.5 g/dL, after adjusting for changes in the control group. To what extent the benefits of iron therapy are mediated by increases in haemoglobin concentration is unclear because there a number of cellular mechanisms that might be influenced by intravenous iron.^{1,23}

Our trial has limitations. IRONMAN recruited a predominantly White population; the results might not generalise well to patients of other ethnicities. The open-label design might have affected visit attendance and more subjective endpoints, such as quality of life or walking distance. The event rate was lower than predicted, in part due to recruiting fewer than expected patients admitted to hospital, causing the trial to be extended further into the COVID-19 pandemic than otherwise would have been the case. Of patients assigned to usual care, 95 (17%) received one or more non-protocol intravenous iron infusions. This will have diluted the magnitude of benefit observed and reduced the power of the trial. A strength of our trial was that record linkage combined with masked adjudication of all hospital admissions and deaths helped ensure complete reporting of clinical events. The trial did not include patients with heart failure and preserved ejection fraction; there is no current evidence to support the routine use of intravenous iron in these patients.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are now commonly used in the treatment of patients with heart failure.^{20,21} Further evidence is required to understand potential interactions between SGLT2 inhibitors and iron status, although data do not suggest that underlying iron deficiency affects their benefit.²⁴

International heart failure guidelines now recommend screening for iron deficiency.^{20,21} Whereas European Society of Cardiology guidelines suggest consideration of intravenous ferric carboxymaltose for symptomatic patients with recent hospital admission for heart failure to reduce further heart failure admissions,²⁰ American guidelines currently do not.²¹ Data from IRONMAN, showing improvements in outcomes in patients with heart failure and both reduced and mildly reduced ejection fraction with ferric derisomaltose, provide further evidence to support the use of intravenous iron in these patients. Ongoing trials (for example NCT03036462 and the trial by Mentz and colleagues²⁵), across a range of ejection fractions, might clarify whether intravenous iron reduces cardiovascular mortality. Randomised trials of patients with heart failure suggest that oral iron might not correct iron deficiency, but these trials were small and relatively short-term.²⁶ Further trials of oral iron might be considered, but parenteral administration of iron is required to correct iron deficiency rapidly; oral iron, even if well absorbed, will take many months to do so.

For a broad range of patients with heart failure, reduced left ventricular ejection fraction, and either a transferrin saturation less than 20% or serum ferritin less than 100 µg/L, the results of treatment with intravenous administration of ferric derisomaltose in the IRONMAN trial suggest a reduced risk of the primary outcome, recurrent hospital admissions for heart failure and cardiovascular death, providing further evidence of the benefits of correcting iron deficiency in this population.

Contributors

PRK, JGFC, PAK, IBS, ICM, and IF conceived the study idea and acquired the funding. MR and IF did the statistical analysis and directly accessed and verified the underlying data reported in the manuscript. PRK, JGFC, MCP, EAT, and IF contributed to project administration. PRK, MCP, PAK, IBS, FZA, AA-M, PJC, PWF, FJG, AGJ, REL, NNL, AJL, PP, RR, and AS contributed to data collection and provision of patients. All authors contributed to data interpretation. PRK and IF wrote the first draft of the manuscript, and all authors reviewed and approved the final version. PRK and IF were responsible for the decision to submit the manuscript. The first draft of this paper was prepared by the first and last authors. It was reviewed by all authors, who made the decision to submit the paper. All authors had access to all the data in the study.

Declaration of interests

PRK reports research grants from British Heart Foundation and Pharmacosmos; consulting fees from Accea, Amgen, Boehringer Ingelheim, Pharmacosmos, Servier, and Vifor Pharma; payment for lectures from AstraZeneca, Bayer, Novartis, Pfizer, Pharmacosmos, and Vifor Pharma; support for attending meetings from Pharmacosmos; is a data safety monitoring board member for the STOP-ACE trial; and has served as Chair of the British Society for Heart Failure. JGFC reports research grants from Amgen, Bayer, Bristol Myers Squibb, British Heart Foundation, Johnson & Johnson, Medtronic, Myokardia, Pharmacosmos, Pharma Nord, and Vifor Pharma; payment for lectures from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Innolife, NI Medical, Novartis, Servier, and Torrent; support for attending meetings from Boehringer Ingelheim and Pharmacosmos; is a data safety monitoring board member for Idorsia and Medtronic; has stock with Heartfelt Limited; and has been provided with equipment by Heartfelt Limited and

NI Medical. MCP reports research grants from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Medtronic, Novartis, Novo Nordisk, Roche, and SQ Innovations; consulting fees from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Novartis, Novo Nordisk, Pharmacosmos, Siemens, and Takeda; payment for lectures from AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Pharmacosmos, Siemens, and Vifor Pharma; support for attending meetings from AstraZeneca; is a data safety monitoring board or advisory board member for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Pharmacosmos, Teikoku, and Vifor Pharma; and is a director of Global Clinical Trials Partners. EAT, MR, and IF report research grants from British Heart Foundation and Pharmacosmos. PAK reports research grant support from Astellas, Evotec, Pharmacosmos, Unicyte, and Vifor Pharma; consulting fees from AstraZeneca, UCB, Unicyte, and Vifor Pharma; payment for lectures from AstraZeneca, Bayer, Napp, Pfizer, Pharmacosmos, and Vifor Pharma; and support for attending meetings from Pharmacosmos and Vifor Pharma. IBS reports a research grant from British Heart Foundation. FZA reports a research grant from Medtronic; consulting fees and payment for lectures from Abbott, AstraZeneca, Medtronic, Pfizer, Pharmacosmos, Servier, and Vifor Pharma; and support for attending meetings from AstraZeneca, Medtronic, and Pharmacosmos. AA-M reports payment for lectures from AstraZeneca, Janssen, Pharmacosmos, and Takeda; is on a data safety monitoring board or advisory board for AstraZeneca, Novartis, and Pharmacosmos; and reports a grant for equipment from AstraZeneca. PWXF reports a research grant, consulting fees, and other support from Medtronic; payment for lectures from Pharmacosmos and Vifor Pharma; and is a council member of British Heart Rhythm Society charity. FJG reports a research grant from British Heart Foundation. AGJ reports payment for lectures from AstraZeneca, Novartis, and Vifor Pharma; and is the clinical lead of the Scottish Heart Failure Hub. REL reports consulting fees from Abbott. NNL reports research grants from AstraZeneca, Boehringer Ingelheim, British Heart Foundation, and Roche Diagnostics; consulting fees from AstraZeneca; payment for lectures from Novartis and Roche Pharma; and is on a data safety monitoring board or advisory board for Pharmacosmos. AJL reports payment for lectures from AstraZeneca; support for attending meetings from Daiichi Sankyo; is on an advisory board for Daiichi Sankyo and Vifor Pharma; and is Chair of the British Cardiovascular Society Guidelines and Practice Committee. ICM reports consulting fees from GlaxoSmithKline and Vifor Pharma. PP reports consulting fees from Pharmacosmos and Vifor Pharma; and support for attending meetings from Bristol Myers Squibb, Pharmacosmos, and Vifor Pharma. RR reports consulting fees from Pharmacosmos; payment for lectures from Pfizer; is on the data monitoring committee for the Lift study; and has a leadership role in the HFA Education Committee. All other authors declare no competing interests.

Data sharing

The IRONMAN investigators welcome proposals for data sharing after the publication of the primary study results and key secondary manuscripts (approximately 2 years after the publication of the primary results). Proposals will be considered by the IRONMAN Publications Committee. Approval will depend on the scientific value of the proposal, compatibility with the original patient consent, and data protection legislation. Preference will be given to proposals for access to aggregate data or analytic results. Applicants will be expected to meet the costs associated with the preparation of data or statistical analysis. Applications should be made to Paul Kalra (paulkalra@doctors.org.uk).

Acknowledgments

The study was funded by the British Heart Foundation (grant award CS/15/1/31175) and Pharmacosmos. Pharmacosmos provided supplies of ferric derisomaltose and supported the trial with an additional unrestricted grant. We thank Public Health Scotland and NHS Digital for the provision of data linkage. We also thank all the participants, physicians, nurses, and other staff who contributed to the IRONMAN study. MCP is supported by the British Heart Foundation Centre of Research Excellence Award (RE/13/5/30177 and RE/18/6/34217).

References

- Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in heart failure: therapeutic approach. *J Am Coll Cardiol* 2018; **71**: 782–93.
- Cleland JG, Zhang J, Pellicori P, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. *JAMA Cardiol* 2016; **1**: 539–47.
- Masini G, Graham FJ, Pellicori P, et al. Criteria for iron deficiency in patients with heart failure. *J Am Coll Cardiol* 2022; **79**: 341–51.
- Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009; **361**: 2436–48.
- Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015; **36**: 657–68.
- Sawicki KT, Ardehali H. Intravenous iron therapy in heart failure with reduced ejection fraction: tackling the deficiency. *Circulation* 2021; **144**: 253–55.
- Ghafourian K, Chang HC, Ardehali H. Intravenous iron therapy in heart failure: a different perspective. *Eur J Heart Fail* 2019; **21**: 703–14.
- Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. *JAMA Netw Open* 2021; **4**: e2133935.
- Kalra PR, Cleland JGF, Petrie MC, et al. Rationale and design of a randomised trial of intravenous iron in patients with heart failure. *Heart* 2022; published online Aug 10. <https://doi.org/10.1136/heartjnl-2022-321304>.
- Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet* 2020; **396**: 1895–904.
- Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. *Clin Res Cardiol* 2021; **110**: 1299–307.
- Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. *J R Stat Soc Series B Stat Methodol* 2000; **62**: 711–30.
- Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. *Biometrics* 2000; **56**: 554–62.
- US Food and Drug Administration. Conduct of clinical trials of medical products during the COVID-19 public health emergency guidance for industry, investigators, and institutional review boards. March, 2020, updated on Aug, 30, 2021. <https://www.fda.gov/media/136238/download> (accessed Oct 8, 2022).
- European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic. Version 5. https://health.ec.europa.eu/system/files/2022-02/guidanceclinicaltrials_covid19_en_1.pdf (accessed Oct 8, 2022).
- Anker SD, Butler J, Khan MS, et al. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an expert consensus position paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J* 2020; **41**: 2109–17.
- Ponikowski P, Kirwan B-A, Anker SD, et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. *Eur J Heart Fail* 2019; **21**: 1651–58.
- Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. *JAMA* 2020; **323**: 432–43.
- Metra M, Jankowska EA, Pagnesi M, et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. *Eur Heart J* 2022; published online July 23. <https://doi.org/10.1002/ehfj.2630>.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021; **42**: 3599–726.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022; **145**: e895–1032.

-
- 22 Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. *N Engl J Med* 2019; **380**: 447–58.
 - 23 Charles-Edwards G, Amaral N, Sleight A, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. *Circulation* 2019; **139**: 2386–98.
 - 24 Docherty KF, Welsh P, Verma S, et al. Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. *Circulation* 2022; **146**: 980–94.
 - 25 Mentz RJ, Ambrosy AP, Ezekowitz JA, et al. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. *Circ Heart Fail* 2021; **14**: e008100.
 - 26 Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. *JAMA* 2017; **317**: 1958–66.